ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Indaptus Therapeutics (INDP)
Indaptus Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$3.28▼ -1.80%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
40%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Indaptus Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Indaptus Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Indaptus Therapeutics a 40% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $2.25 and $3.91; in 9 out of 10, between $1.38 and $6.37. Estimated annual volatility is 176%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $317M
- 52-week high
- $4.75
- 52-week low
- $0.92
- Revenue (12 months)
- $0.0M
- Return on equity
- -318.0%
- Free cash flow (12 months)
- $-9.7M
- Beta
- 1.17
What this means
ATLAS does not publish a fair value for INDP right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks INDP has traded between $0.92 and $4.75. Today it is 31.0% below that high and 257% above its low.
Its beta is 1.17: it tends to move more than the market, both up and down.
About the company
Indaptus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing immunotherapy products for cancer and viral infections.
Want to see everything about Indaptus Therapeutics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Indaptus Therapeutics do?
Indaptus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing immunotherapy products for cancer and viral infections.
What is the chance INDP goes up next month?
40%: somewhat worse than a coin flip. In half of the simulated outcomes, INDP ends the month between $2.25 and $3.91.
How big is Indaptus Therapeutics and what is its P/E ratio?
Indaptus Therapeutics's market capitalization is $317M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is INDP?
ATLAS estimates annual volatility at 176%. In a typical month, half of the outcomes end between $2.25 and $3.91.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer